PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition
Jennifer M Spangle1, Thanh Von2,3, Dean C Pavlick4
1Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115; jennifer.spangle@emory.edu thomas_roberts@dfci.harvard.edu.
Abstract:
PIK3CA hotspot mutation is well established as an oncogenic driver event in cancer and its durable and efficacious inhibition is a focus in the development and testing of clinical cancer therapeutics. However, hundreds of cancer-associated PIK3CA mutations remain uncharacterized, their sensitivity to PI3K inhibitors unknown. Here, we describe a series of PIK3CA C-terminal mutations, primarily nucleotide insertions, that produce a frame-shifted protein product with an extended C terminus. We report that these mutations occur at a low frequency across multiple cancer subtypes, including breast, and are sufficient to drive oncogenic transformation in vitro and in vivo. We demonstrate that the oncogenicity of these mutant p110α proteins is dependent on p85 but not Ras association. P110α-selective pharmacologic inhibition blocks transformation in cells and mammary tumors characterized by PIK3CA C-terminal mutation. Taken together, these results suggest patients with breast and other tumors characterized by PIK3CA C-terminal frameshift mutations may derive benefit from p110α-selective inhibitors, including the recently FDA-approved alpelisib.
Insights
New PIK3CA C-terminal mutations drive cancer and respond to p110α-selective inhibitors. These findings suggest potential benefits for patients with PIK3CA-mutated breast and other cancers treated with targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- PIK3CA hotspot mutations are known oncogenic drivers in cancer.
- Many PIK3CA mutations remain uncharacterized, limiting targeted therapy development.
- PI3K pathway dysregulation is crucial in cancer progression.
Purpose of the Study:
- To characterize novel PIK3CA C-terminal mutations.
- To assess the oncogenic potential and therapeutic sensitivity of these mutations.
- To evaluate the efficacy of p110α-selective inhibitors against these mutations.
Main Methods:
- Analysis of PIK3CA C-terminal mutations, including nucleotide insertions.
- In vitro and in vivo studies to assess oncogenic transformation.
- Pharmacologic inhibition using p110α-selective agents.
- Assessment of p85 and Ras association with mutant p110α proteins.
Main Results:
- Identified PIK3CA C-terminal mutations causing frame-shifts and extended protein products.
- These mutations, though infrequent, drive oncogenic transformation in vitro and in vivo.
- Oncogenicity depends on p85 association but not Ras association.
- P110α-selective inhibition effectively blocks transformation in affected cells and tumors.
Conclusions:
- PIK3CA C-terminal frameshift mutations are oncogenic drivers.
- These mutations sensitize tumors to p110α-selective inhibitors.
- Patients with PIK3CA C-terminal frameshift mutations may benefit from therapies like alpelisib.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Ras Gene
Ras is a...
Point and Frameshift Mutations
